Cell type-associated traits map for the [Madissoon_2020_lung_Muscle cells][link to cell ontology]. Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-04 as default, and users can change it to 1e-03, 1e-05, or 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple TAG sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below.” The association association is listed in the table at bottom, Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns).
Table. List of Cell type-associated traits pairs for [Madissoon_2020_lung_Muscle cells]. If the network above is too complicated. the users could obtain the association information from the table at bottom. Because each trait has multiple TAG sets defined at different thresholds, there may be multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Trait Name | Trait Full Name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|
ADHD | Attention Deficit Hyperactivity Disorder | ETC | Demontis | 2017 | 19099 | 34194 | 5.00e-2 | 1.87e-2 |
ADHD | Attention Deficit Hyperactivity Disorder | MTC | Middeldorp | 2016 | NA | 17666 | 5.00e-2 | 5.32e-3 |
ADHD | Attention Deficit Hyperactivity Disorder | MTC | Middeldorp | 2016 | NA | 17666 | 1.00e-2 | 2.32e-2 |
Age At Death | Age At Death | MTC | Pilling | 2016 | NA | 45627 | 1.00e-2 | 5.78e-3 |
Aggression | Aggression | MTC | Pappa | 2015 | NA | 15668 | 5.00e-2 | 2.42e-3 |
Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 5.00e-2 | 1.69e-2 |
Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | MTC | van-Rheenen | 2016 | 12577 | 23475 | 5.00e-2 | 4.99e-2 |
Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | MTC | van-Rheenen | 2016 | 12577 | 23475 | 1.00e-2 | 2.42e-2 |
BIP | Bipolar Disorder | MTC | Psychiatric-Genomics-Consortium | 2012 | 7481 | 9250 | 5.00e-2 | 8.56e-4 |
BIP | Bipolar Disorder | MTC | Psychiatric-Genomics-Consortium | 2012 | 7481 | 9250 | 1.00e-2 | 2.19e-3 |
BIP | Bipolar Disorder | MTC | Psychiatric-Genomics-Consortium | 2012 | 7481 | 9250 | 1.00e-3 | 1.47e-2 |
BIP | Bipolar Disorder | MTC | Psychiatric-Genomics-Consortium | 2012 | 7481 | 9250 | 1.00e-4 | 1.82e-2 |
BIP | Bipolar Disorder | MTC | Psychiatric-Genomics-Consortium | 2012 | 7481 | 9250 | 1.00e-5 | 1.56e-2 |
Birth Weight | Birth Weight | MTC | Horikoshi | 2013 | NA | 26836 | 5.00e-2 | 5.14e-3 |
Birth Weight | Birth Weight | MTC | Horikoshi | 2013 | NA | 26836 | 1.00e-2 | 3.32e-2 |
Blood Pressure | Blood Pressure | MTC | Ehret | 2011 | NA | 69395 | 5.00e-2 | 5.81e-4 |
Blood Pressure | Blood Pressure | MTC | Ehret | 2011 | NA | 69395 | 1.00e-2 | 7.06e-3 |
BMI Childhood | BMI Childhood | MTC | Felix | 2015 | NA | 34744 | 1.00e-4 | 2.69e-2 |
BMI | Body Mass Index | MTC | Speliotes | 2010 | NA | 123865 | 5.00e-2 | 1.83e-2 |
Bone Mineral Density Estimated | Bone Mineral Density Estimated | MTC | Kemp | 2017 | NA | 142487 | 1.00e-3 | 6.42e-5 |
Bone Mineral Density Estimated | Bone Mineral Density Estimated | MTC | Kemp | 2017 | NA | 142487 | 1.00e-4 | 1.71e-3 |
Bone Mineral Density Estimated | Bone Mineral Density Estimated | MTC | Kemp | 2017 | NA | 142487 | 1.00e-5 | 3.55e-3 |
Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 5.00e-2 | 2.20e-3 |
Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 5.00e-2 | 3.46e-2 |
CAD | Coronary Artery Disease | MTC | C4D | 2011 | 64762 | 22233 | 5.00e-2 | 3.44e-2 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 5.00e-2 | 1.27e-4 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-2 | 6.38e-3 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-3 | 4.41e-3 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-5 | 1.60e-2 |
CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 5.00e-2 | 3.95e-5 |
CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-2 | 3.55e-3 |
CAD | Coronary Artery Disease | MTC | Schunkert | 2011 | 22233 | 64762 | 1.00e-3 | 1.22e-2 |
Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 1.68e-5 |
Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 1.75e-3 |
Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 5.00e-2 | 1.68e-5 |
Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 1.00e-2 | 1.75e-3 |
Gout | Gout | MTC | Kottgen | 2013 | 2115 | 67259 | 5.00e-2 | 1.25e-2 |
Gout | Gout | MTC | Kottgen | 2013 | 2115 | 67259 | 1.00e-2 | 1.58e-3 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-2 | 3.01e-3 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-3 | 2.06e-2 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-4 | 4.60e-2 |
Insomnia | Insomnia | MTC | Hammerschlag | 2017 | 12863 | 40776 | 5.00e-2 | 9.90e-4 |
Insomnia | Insomnia | MTC | Hammerschlag | 2017 | 12863 | 40776 | 1.00e-2 | 6.75e-4 |
Insomnia | Insomnia | MTC | Hammerschlag | 2017 | 12863 | 40776 | 1.00e-3 | 2.82e-2 |
Intelligence | Intelligence | MTC | Sniekers | 2017 | NA | 78308 | 5.00e-2 | 2.71e-3 |
Internalizing Problems | Internalizing Problems | ETC | Benke | 2014 | NA | 4596 | 1.00e-2 | 4.20e-2 |
Longevity | Longevity | MTC | Broer | 2015 | 6036 | 3757 | 5.00e-2 | 2.67e-4 |
Longevity | Longevity | MTC | Broer | 2015 | 6036 | 3757 | 1.00e-2 | 1.64e-2 |
Longevity | Longevity | MTC | Broer | 2015 | 6036 | 3757 | 1.00e-3 | 1.05e-2 |
MDD | Major Depressive Disorder | MTC | McMahon | 2010 | 6686 | 9068 | 5.00e-2 | 1.04e-2 |
MDD | Major Depressive Disorder | MTC | McMahon | 2010 | 6686 | 9068 | 1.00e-2 | 1.63e-2 |
MDD | Major Depressive Disorder | MTC | McMahon | 2010 | 6686 | 9068 | 1.00e-4 | 8.36e-3 |
MDD | Major Depressive Disorder | MTC | PGC | 2013 | 9240 | 9519 | 5.00e-2 | 8.66e-3 |
MDD | Major Depressive Disorder | MTC | PGC | 2013 | 9240 | 9519 | 1.00e-2 | 4.36e-2 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-2 | 1.96e-2 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-3 | 3.68e-2 |
Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-4 | 1.20e-2 |
Neuroticism Symptoms | Neuroticism Symptoms | ETC | Okbay | 2016 | NA | 170911 | 5.00e-2 | 1.94e-2 |
Offspring Birth Weight | Offspring Birth Weight | MTC | Beaumont | 2018 | NA | 68258 | 5.00e-2 | 2.82e-3 |
Offspring Birth Weight | Offspring Birth Weight | MTC | Beaumont | 2018 | NA | 68258 | 1.00e-2 | 1.08e-2 |
Offspring Birth Weight | Offspring Birth Weight | MTC | Beaumont | 2018 | NA | 68258 | 1.00e-4 | 1.05e-2 |
Offspring Birth Weight | Offspring Birth Weight | MTC | Beaumont | 2018 | NA | 68258 | 1.00e-5 | 2.57e-2 |
Partial Epilepsy | Partial Epilepsy | MTC | Kasperaviciute | 2010 | 3445 | 6935 | 1.00e-3 | 3.51e-3 |
Prostate Cancer | Prostate Cancer | MTC | Yeager | 2007 | 1172 | 1157 | 1.00e-2 | 3.14e-2 |
Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 5.00e-2 | 6.86e-4 |
Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 1.00e-2 | 1.58e-3 |
Tiredness | Tiredness | MTC | Deary | 2018 | NA | 108976 | 5.00e-2 | 3.94e-2 |
Tiredness | Tiredness | MTC | Deary | 2018 | NA | 108976 | 1.00e-2 | 7.89e-3 |
Tiredness | Tiredness | MTC | Deary | 2018 | NA | 108976 | 1.00e-3 | 7.77e-4 |
Tiredness | Tiredness | MTC | Deary | 2018 | NA | 108976 | 1.00e-4 | 1.30e-2 |
Type 2 Diabetes | Type 2 Diabetes | ETC | Morris | 2012 | 12171 | 56862 | 5.00e-2 | 2.61e-2 |
Visual Refractive Error | Visual Refractive Error | MTC | Stambolian | 2013 | NA | 7280 | 5.00e-2 | 1.17e-2 |
Visual Refractive Error | Visual Refractive Error | MTC | Stambolian | 2013 | NA | 7280 | 1.00e-2 | 2.63e-2 |
Vitamin D | Vitamin D | MTC | Manousaki | 2017 | NA | 42274 | 5.00e-2 | 3.86e-2 |
Albuminuria | Microalbuminuria | MTC | Boger | 2011 | NA | 31580 | 5.00e-2 | 4.47e-3 |
Albuminuria | Microalbuminuria | MTC | Teumer | 2016 | NA | 54116 | 5.00e-2 | 2.02e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 1.00e-2 | 7.69e-3 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Nondiabetics | MTC | Teumer | 2016 | NA | 46051 | 5.00e-2 | 2.11e-2 |
Alcohol Consumption | Alcohol Consumption All Continuous | MTC | Schumann | 2016 | NA | 70460 | 1.00e-3 | 4.62e-2 |
Alcohol Consumption | Alcohol Consumption All Continuous | MTC | Schumann | 2016 | NA | 70460 | 1.00e-4 | 2.21e-2 |
Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 5.00e-2 | 4.27e-3 |
Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 1.00e-2 | 9.14e-3 |
Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 5.00e-2 | 1.88e-2 |
Alcohol Consumption | Alcohol Consumption Women Dichotomous | MTC | Schumann | 2016 | NA | 47720 | 5.00e-2 | 1.77e-2 |
Alcohol Consumption | Alcohol Consumption Women Dichotomous | MTC | Schumann | 2016 | NA | 47720 | 1.00e-2 | 1.11e-2 |
Alzheimers Protein Levels | Amyloid Beta 1 42 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 4.48e-4 |
Anthropometric Extremes | Extreme BMI | MTC | Berndt | 2013 | 7962 | 8106 | 5.00e-2 | 1.17e-2 |
Anthropometric Extremes | Extreme BMI | MTC | Berndt | 2013 | 7962 | 8106 | 1.00e-2 | 7.26e-3 |
Anthropometric Extremes | Extreme Height | MTC | Berndt | 2013 | 8097 | 8099 | 5.00e-2 | 3.10e-5 |
Anthropometric Extremes | Extreme Height | MTC | Berndt | 2013 | 8097 | 8099 | 1.00e-2 | 1.07e-2 |
Anthropometric Extremes | Extreme Waist Hip Ratio | MTC | Berndt | 2013 | 4774 | 5481 | 5.00e-2 | 4.37e-2 |
Anthropometric Extremes | Obesity Class 1 | MTC | Berndt | 2013 | 32858 | 65840 | 5.00e-2 | 4.94e-2 |
Anthropometric Extremes | Obesity Class 3 | MTC | Berndt | 2013 | 2896 | 65840 | 5.00e-2 | 4.28e-2 |
Anthropometrics Sex Stratified | Body Mass Index Men | MTC | Randall | 2013 | 60586 | 60856 | 5.00e-2 | 8.48e-3 |
Anthropometrics Sex Stratified | Body Mass Index Men | MTC | Randall | 2013 | 60586 | 60856 | 1.00e-3 | 3.24e-2 |
Anthropometrics Sex Stratified | Body Mass Index Men | MTC | Randall | 2013 | 60586 | 60856 | 1.00e-4 | 4.79e-2 |
Anthropometrics Sex Stratified | Height Men | MTC | Randall | 2013 | NA | 60856 | 5.00e-2 | 4.03e-2 |
Anthropometrics Sex Stratified | Height Women | MTC | Randall | 2013 | NA | 73137 | 5.00e-2 | 4.94e-4 |
Anthropometrics Sex Stratified | Height Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-2 | 3.12e-3 |
Anthropometrics Sex Stratified | Height Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-4 | 1.91e-2 |
Anthropometrics Sex Stratified | Height Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-5 | 2.01e-2 |
Anthropometrics Sex Stratified | Hip Circumference Men | MTC | Randall | 2013 | NA | 34942 | 5.00e-2 | 3.67e-3 |
Anthropometrics Sex Stratified | Hip Circumference Men | MTC | Randall | 2013 | NA | 34942 | 1.00e-3 | 4.45e-3 |
Anthropometrics Sex Stratified | Hip Circumference Women | MTC | Randall | 2013 | NA | 43316 | 5.00e-2 | 1.31e-2 |
Anthropometrics Sex Stratified | Hip Circumference Women | MTC | Randall | 2013 | NA | 43316 | 1.00e-2 | 1.17e-4 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Men | MTC | Randall | 2013 | NA | 36231 | 5.00e-2 | 2.59e-2 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Men | MTC | Randall | 2013 | NA | 36231 | 1.00e-3 | 6.39e-3 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 45192 | 5.00e-2 | 1.94e-3 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 45192 | 1.00e-2 | 1.22e-2 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 45192 | 1.00e-3 | 8.67e-3 |
Anthropometrics Sex Stratified | Waist Circumference Men | MTC | Randall | 2013 | NA | 36231 | 5.00e-2 | 2.52e-3 |
Anthropometrics Sex Stratified | Waist Circumference Men | MTC | Randall | 2013 | NA | 36231 | 1.00e-2 | 4.52e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Men | MTC | Randall | 2013 | NA | 34629 | 5.00e-2 | 1.96e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Women | MTC | Randall | 2013 | NA | 42969 | 5.00e-2 | 1.29e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Women | MTC | Randall | 2013 | NA | 42969 | 1.00e-2 | 3.61e-4 |
Anthropometrics Sex Stratified | Weight Men | MTC | Randall | 2013 | NA | 60856 | 5.00e-2 | 7.45e-3 |
Anthropometrics Sex Stratified | Weight Men | MTC | Randall | 2013 | NA | 60856 | 1.00e-2 | 2.72e-2 |
Anxiety | Anxiety Continuous | ETC | Otowa | 2016 | NA | 18186 | 5.00e-2 | 3.37e-2 |
Anxiety | Anxiety Continuous | ETC | Otowa | 2016 | NA | 18186 | 1.00e-2 | 3.36e-4 |
Aortic Valve Calcification | Mitral Annular Calcification | MTC | Thanassoulis | 2013 | NA | 3795 | 1.00e-2 | 6.20e-3 |
Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 1.00e-2 | 2.09e-3 |
Birth Weight | Birth Weight European | ETC | Horikoshi | 2016 | NA | 133903 | 1.00e-2 | 5.73e-3 |
Blood Cells | Basophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.54e-2 |
Blood Cells | Basophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 1.76e-2 |
Blood Cells | Platelet Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 4.18e-2 |
Blood Cells | Red Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.27e-3 |
Blood Cells | Red Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 1.52e-2 |
Blood Lipids | High Density Lipoprotein | ETC | Teslovich | 2010 | NA | 99900 | 5.00e-2 | 3.94e-2 |
Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 4.76e-2 |
BMI Age Stratified | BMI Men Age Over 50 | MTC | Winkler | 2015 | NA | 90988 | 5.00e-2 | 9.86e-4 |
BMI Age Stratified | BMI Men Age Over 50 | MTC | Winkler | 2015 | NA | 90988 | 1.00e-2 | 1.89e-2 |
BMI Age Stratified | BMI Men Age Under 50 | MTC | Winkler | 2015 | NA | 51625 | 5.00e-2 | 1.40e-2 |
BMI Age Stratified | BMI Men Age Under 50 | MTC | Winkler | 2015 | NA | 51625 | 1.00e-2 | 2.39e-2 |
BMI Age Stratified | BMI Women Age Over 50 | MTC | Winkler | 2015 | NA | 106622 | 5.00e-2 | 1.61e-3 |
BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Men Under 50 | MTC | Winkler | 2015 | NA | 43776 | 5.00e-2 | 8.99e-5 |
BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Men Under 50 | MTC | Winkler | 2015 | NA | 43776 | 1.00e-2 | 1.71e-2 |
BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Women Under 50 | MTC | Winkler | 2015 | NA | 50526 | 5.00e-2 | 2.48e-2 |
BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Women Under 50 | MTC | Winkler | 2015 | NA | 50526 | 1.00e-2 | 1.35e-2 |
BMI | BMI European | ETC | Locke | 2015 | NA | 234069 | 5.00e-2 | 4.81e-2 |
BMI | BMI European | ETC | Locke | 2015 | NA | 234069 | 1.00e-2 | 4.32e-2 |
BMI | BMI European Men | MTC | Locke | 2015 | NA | 104666 | 5.00e-2 | 1.64e-2 |
BMI | BMI European Men | MTC | Locke | 2015 | NA | 104666 | 1.00e-2 | 1.18e-2 |
BMI | BMI European Men | MTC | Locke | 2015 | NA | 104666 | 1.00e-3 | 1.79e-2 |
BMI | BMI European Women | MTC | Locke | 2015 | NA | 132115 | 5.00e-2 | 4.72e-2 |
BMI Physical Activity Interaction | BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 4.92e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 5.49e-6 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 3.96e-5 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 9.00e-4 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 3.96e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 1.85e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 6.61e-6 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.37e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 1.05e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 3.76e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 2.46e-4 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 2.06e-4 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 3.58e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 2.31e-5 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 1.70e-4 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 1.06e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 4.15e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 7.71e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 1.11e-5 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 2.75e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 1.24e-4 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 3.62e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 1.64e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 2.31e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 9.38e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 4.65e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 6.10e-5 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 2.42e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 2.60e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 1.93e-4 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 2.09e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 2.57e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 9.99e-4 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 4.20e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 1.91e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 4.54e-5 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.07e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 2.86e-4 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 3.54e-3 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 2.67e-2 |
BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 8.38e-3 |
BMI Smoking Adjusted | BMI Smoking Adjusted Men European | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 1.66e-2 |
BMI Smoking Adjusted | BMI Smoking Adjusted Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 8.59e-3 |
BMI Smoking Adjusted | BMI Smoking Adjusted Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 3.82e-2 |
BMI Smoking Adjusted | BMI Smoking Adjusted Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-5 | 2.14e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 4.82e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 4.71e-4 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 2.38e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 2.74e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 1.93e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 2.17e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.92e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 3.68e-5 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 1.00e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 2.95e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 4.62e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.61e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 3.66e-2 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 7.98e-3 |
BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 7.43e-3 |
Bone Mineral Density | Femoral Neck Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 32961 | 1.00e-4 | 4.43e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density Women | MTC | Estrada | 2012 | NA | 32961 | 1.00e-5 | 4.89e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density All | MTC | Estrada | 2012 | NA | 31800 | 5.00e-2 | 3.98e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 30 to 45 | MTC | Medina-Gomez | 2018 | NA | 10062 | 5.00e-2 | 1.66e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 30 to 45 | MTC | Medina-Gomez | 2018 | NA | 10062 | 1.00e-4 | 4.08e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 45 to 60 | MTC | Medina-Gomez | 2018 | NA | 18805 | 5.00e-2 | 3.36e-3 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 45 to 60 | MTC | Medina-Gomez | 2018 | NA | 18805 | 1.00e-2 | 3.05e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 45 to 60 | MTC | Medina-Gomez | 2018 | NA | 18805 | 1.00e-3 | 3.49e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 60 And More | MTC | Medina-Gomez | 2018 | NA | 22504 | 5.00e-2 | 4.20e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 5.00e-2 | 1.61e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-2 | 1.63e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-3 | 3.09e-3 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-4 | 7.72e-4 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-5 | 4.31e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density | ETC | Zheng | 2015 | NA | 26320 | 5.00e-2 | 3.02e-2 |
Bone Mineral Density | Femoral Neck Bone Mineral Density | ETC | Zheng | 2015 | NA | 26320 | 1.00e-2 | 4.14e-3 |
Bone Mineral Density | Femoral Neck Bone Mineral Density | ETC | Zheng | 2015 | NA | 26320 | 1.00e-3 | 2.68e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 5.00e-2 | 6.49e-3 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 1.00e-2 | 1.32e-2 |
Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-2 | 3.75e-2 |
Cognitive Functions | College | MTC | Davies | 2016 | NA | 111114 | 5.00e-2 | 4.10e-3 |
Cognitive Functions | Verbal Numeric Reasoning | MTC | Davies | 2016 | NA | 36035 | 5.00e-2 | 3.69e-3 |
Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 5.00e-2 | 1.05e-7 |
Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-2 | 2.39e-4 |
Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-3 | 1.63e-2 |
Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-4 | 4.18e-2 |
Coronary Artery Disease | Coronary Artery Disease Recessive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 5.00e-2 | 1.44e-2 |
Coronary Artery Disease | Coronary Artery Disease Recessive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-2 | 2.36e-2 |
Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 5.00e-2 | 3.10e-5 |
Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 1.00e-2 | 1.16e-3 |
Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 1.00e-3 | 4.10e-3 |
Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 1.00e-4 | 3.81e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 1.00e-2 | 1.48e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 1.00e-3 | 1.82e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14668 | 5.00e-2 | 9.11e-3 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-2 | 2.30e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation All | MTC | Chu | 2017 | NA | 11398 | 5.00e-2 | 3.27e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Men | MTC | Chu | 2017 | NA | 5699 | 5.00e-2 | 4.97e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Women | MTC | Chu | 2017 | NA | 5699 | 5.00e-2 | 3.04e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14780 | 5.00e-2 | 1.20e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7399 | 5.00e-2 | 3.59e-3 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7399 | 1.00e-2 | 1.25e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Attenutation All | MTC | Chu | 2017 | NA | 11478 | 5.00e-2 | 1.55e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Attenutation All | MTC | Chu | 2017 | NA | 11478 | 1.00e-2 | 2.22e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 5.00e-2 | 5.12e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 1.00e-2 | 1.91e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 1.00e-3 | 2.50e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 2.12e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 1.29e-5 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 1.00e-2 | 8.99e-4 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7431 | 5.00e-2 | 4.02e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-2 | 1.19e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-3 | 8.91e-5 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 5.00e-2 | 1.36e-2 |
Educational Attainment | Education Years Women | MTC | Okbay | 2016 | 0 | 293723 men and women | 1.00e-2 | 3.98e-2 |
Estimated Glomerular Filtration Rate | Chronic Kidney Disease | ETC | Pattaro | 2016 | 12385 | 104780 | 1.00e-4 | 4.78e-2 |
Estimated Glomerular Filtration Rate | Chronic Kidney Disease Without Diabetes | MTC | Pattaro | 2016 | NA | 118448 | 5.00e-2 | 3.29e-3 |
Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 5.00e-2 | 2.51e-2 |
Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 1.00e-2 | 4.99e-2 |
Estimated Glomerular Filtration Rate | Serum Creatinine | MTC | Pattaro | 2016 | NA | 133413 | 5.00e-2 | 1.61e-3 |
Estimated Glomerular Filtration Rate | Serum Creatinine | MTC | Pattaro | 2016 | NA | 133413 | 1.00e-2 | 2.28e-2 |
Estimated Glomerular Filtration Rate | Serum Creatinine African Americans Only | MTC | Pattaro | 2016 | NA | 133413 | 5.00e-2 | 2.56e-3 |
Estimated Glomerular Filtration Rate | Serum Creatinine African Americans Only | MTC | Pattaro | 2016 | NA | 133413 | 1.00e-2 | 3.14e-2 |
Facial Shape | Mod1 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.29e-2 |
Facial Shape | Mod12 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.94e-3 |
Facial Shape | Mod13 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.65e-3 |
Facial Shape | Mod13 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.49e-3 |
Facial Shape | Mod15 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 9.31e-3 |
Facial Shape | Mod18 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.83e-5 |
Facial Shape | Mod18 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.59e-3 |
Facial Shape | Mod19 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.77e-7 |
Facial Shape | Mod19 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.16e-3 |
Facial Shape | Mod25 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.74e-3 |
Facial Shape | Mod25 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.35e-2 |
Facial Shape | Mod26 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.30e-3 |
Facial Shape | Mod26 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.78e-3 |
Facial Shape | Mod28 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.67e-2 |
Facial Shape | Mod30 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.69e-2 |
Facial Shape | Mod34 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.44e-2 |
Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 5.86e-3 |
Facial Shape | Mod37 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 6.31e-4 |
Facial Shape | Mod38 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.38e-2 |
Facial Shape | Mod39 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 5.58e-3 |
Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.27e-2 |
Facial Shape | Mod43 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.67e-2 |
Facial Shape | Mod45 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 6.86e-3 |
Facial Shape | Mod50 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.63e-2 |
Facial Shape | Mod52 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.02e-3 |
Facial Shape | Mod52 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.15e-2 |
Facial Shape | Mod53 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.63e-2 |
Facial Shape | Mod55 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 2.37e-2 |
Facial Shape | Mod56 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.47e-2 |
Facial Shape | Mod57 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 9.38e-3 |
Facial Shape | Mod6 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.17e-3 |
Facial Shape | Mod6 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.13e-2 |
Facial Shape | Mod9 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.68e-2 |
Forced Expiratory Volume | Forced Expiratory Volume | MTC | Soler-Artigas | 2015 | NA | 38199 | 5.00e-2 | 1.38e-2 |
Forced Expiratory Volume | Forced Expiratory Volume Over Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 5.00e-2 | 3.75e-4 |
Forced Expiratory Volume | Forced Expiratory Volume Over Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-2 | 8.61e-3 |
Forced Expiratory Volume | Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 5.00e-2 | 1.20e-3 |
Forced Expiratory Volume | Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 1.00e-2 | 5.19e-4 |
Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 1.00e-2 | 1.16e-3 |
Gestational Weight Gain | Late Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 8641 | 1.00e-3 | 2.62e-2 |
Gestational Weight Gain | Total Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 10555 | 1.00e-2 | 1.90e-2 |
Gestational Weight Gain | Total Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 10555 | 1.00e-3 | 3.40e-2 |
Glucose Stimulated Insulin Secretion | Corrected Insulin Response | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 4.75e-2 |
Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 6.44e-3 |
Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 5.25e-4 |
Glucose Stimulated Insulin Secretion | Insulin Sensitivity Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 4.72e-2 |
Glycemic Traits | Fasting Glucose | ETC | Dupuis | 2010 | NA | 46186 | 5.00e-2 | 1.89e-2 |
Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 5.00e-2 | 5.42e-3 |
Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-2 | 3.56e-2 |
Insulin Secretion | Acute Insulin Response | MTC | Wood | 2017 | NA | 2087 | 5.00e-2 | 3.18e-2 |
Insulin Secretion | Peak Insulin Response | MTC | Wood | 2017 | NA | 2159 | 1.00e-2 | 4.92e-3 |
Insulin Sensitivity Index | Model 1 | MTC | Walford | 2016 | NA | 16753 | 1.00e-2 | 1.60e-2 |
Insulin Sensitivity Index | Model 1 | MTC | Walford | 2016 | NA | 16753 | 1.00e-3 | 2.29e-2 |
Insulin Sensitivity Index | Model 2 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 3.56e-2 |
Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 7.13e-3 |
Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 5.00e-2 | 4.80e-5 |
Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 1.00e-2 | 5.88e-3 |
Intracerebral Hemorrhage | Lobar ICH | MTC | Woo | 2014 | 664 | 1481 | 1.00e-2 | 5.58e-4 |
Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 5.00e-2 | 5.31e-4 |
Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 1.00e-2 | 6.73e-3 |
Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 1.00e-2 | 9.74e-3 |
Ischaemic Stroke | Small Vessel Disease | MTC | Traylor | 2012 | 2275 | 12285 | 1.00e-2 | 1.49e-2 |
Ischaemic Stroke | Small Vessel Disease | MTC | Traylor | 2012 | 2275 | 12285 | 1.00e-3 | 3.22e-2 |
Kidney Function | CKDi25 | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 2.29e-2 |
Kidney Function | CKDi25 | MTC | Gorski | 2015 | NA | 45530 | 1.00e-2 | 1.47e-2 |
Kidney Function | Serum Creatinine | MTC | Gorski | 2017 | NA | 45530 | 5.00e-2 | 1.99e-2 |
Kidney Function | Serum Creatinine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-2 | 1.36e-2 |
Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-2 | 2.89e-2 |
Kidney Function | Chronic Kidney Disease | MTC | Kottgen | 2010 | NA | 67093 | 5.00e-2 | 4.36e-3 |
Kidney Function | Serum Creatinine | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-2 | 2.45e-2 |
Kidney Function | Serum Creatinine | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-3 | 2.74e-2 |
Kidney Function | Serum Creatinine | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-5 | 1.97e-2 |
Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-3 | 1.44e-2 |
Lean Body Mass | Appendicular Lean Mass | MTC | Zillikens | 2017 | NA | 28330 | 5.00e-2 | 1.66e-2 |
Leptin | Leptin Not Adjusted For BMI | ETC | Kilpelainen | 2016 | NA | 32161 | 5.00e-2 | 1.18e-2 |
Leptin | Leptin Not Adjusted For BMI | ETC | Kilpelainen | 2016 | NA | 32161 | 1.00e-3 | 5.94e-3 |
Lipoprotein Concentrations | High Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 4.99e-2 |
Lipoprotein Concentrations | Triglycerides | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 3.05e-2 |
Loneliness | Case Control | MTC | Gao | 2017 | 1632 | 3164 | 5.00e-2 | 3.94e-2 |
Loneliness | Loneliness | MTC | Gao | 2017 | NA | 6924 | 1.00e-3 | 1.55e-2 |
Longevity | Age 85 Or Greater | MTC | Deelen | 2014 | 7729 | 16121 | 5.00e-2 | 3.78e-2 |
Longevity | Age 85 Or Greater | MTC | Deelen | 2014 | 7729 | 16121 | 1.00e-3 | 4.89e-2 |
Longevity | Age 90 Or Greater | MTC | Deelen | 2014 | 5406 | 15112 | 1.00e-2 | 1.71e-2 |
Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 7.53e-3 |
Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 3.25e-2 |
TB LM | Total body lean mass | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 2.88e-3 |
TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 1.38e-2 |
New Onset Diabetes | New Onset Diabetes After Drugs, European American | MTC | Chang | 2018 | 138 | 414 | 5.00e-2 | 4.16e-2 |
Pubertal Anthropometrics | Height 10 Year Females | MTC | Cousminer | 2013 | NA | 14040 | 1.00e-3 | 4.00e-2 |
Pubertal Anthropometrics | Height 10 Year Females And 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 5.00e-2 | 1.24e-3 |
Pubertal Anthropometrics | Height 10 Year Females And 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 1.00e-2 | 4.69e-2 |
Pubertal Anthropometrics | Late Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 1.25e-2 |
Pubertal Anthropometrics | Late Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-2 | 1.04e-2 |
Pubertal Anthropometrics | Total Pubertal Height Increase | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 2.46e-3 |
Pubertal Anthropometrics | Total Pubertal Height Increase Females | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 4.82e-3 |
Pubertal Anthropometrics | Total Pubertal Height Increase Females | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-2 | 1.64e-3 |
Pubertal Anthropometrics | Total Pubertal Height Increase Females | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-3 | 4.79e-2 |
Reproductive Behavior | Age First Birth Female | MTC | Barban | 2016 | NA | 189656 | 5.00e-2 | 7.05e-3 |
Reproductive Behavior | Age First Birth Male | MTC | Barban | 2016 | NA | 48408 | 1.00e-2 | 3.28e-2 |
Reproductive Behavior | Age First Birth Pooled | ETC | Barban | 2016 | NA | 238064 | 1.00e-2 | 4.93e-3 |
Reproductive Behavior | Number Children Even Born Pooled | MTC | Barban | 2016 | NA | 329139 | 5.00e-2 | 2.95e-3 |
Reproductive Behavior | Number Children Ever Born Female | MTC | Barban | 2016 | NA | 225230 | 5.00e-2 | 1.67e-3 |
Reproductive Behavior | Number Children Ever Born Female | MTC | Barban | 2016 | NA | 225230 | 1.00e-2 | 2.22e-2 |
Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 5.00e-2 | 1.07e-4 |
Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 1.00e-2 | 4.81e-2 |
Sleep Duration | Average Sleep Duration | MTC | Jones | 2016 | NA | 127573 | 1.00e-2 | 2.21e-2 |
Stroke (ischemic) | All Ischemic Stroke | MTC | Traylor | 2017 | 12389 | 62004 | 5.00e-2 | 1.62e-2 |
Stroke (ischemic) | Cardioembolic Stroke | MTC | Traylor | 2017 | 2365 | 62004 | 5.00e-2 | 4.36e-2 |
Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 5.00e-2 | 1.76e-7 |
Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 1.00e-2 | 1.01e-5 |
Smoking | Ever Vs Never Smoked Discrete | MTC | Furberg | 2010 | 39022 | 30387 | 1.00e-3 | 4.55e-3 |
Smoking | Log Age Onset Smoking | MTC | Furberg | 2010 | NA | 22438 | 5.00e-2 | 7.41e-3 |
Smoking | Log Age Onset Smoking | MTC | Furberg | 2010 | NA | 22438 | 1.00e-3 | 1.78e-2 |
Social Deprivation | Household Income | MTC | Hill | 2016 | NA | 112005 | 5.00e-2 | 1.44e-2 |
Social Deprivation | Household Income One Person Per Household | MTC | Hill | 2016 | NA | 112005 | 5.00e-2 | 4.69e-3 |
Social Deprivation | Townsend Score | MTC | Hill | 2016 | NA | 96900 | 5.00e-2 | 1.21e-2 |
Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 4.91e-2 |
Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 2.14e-2 |
Statin Efficacy | Delta LDL | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 3.31e-4 |
Statin Efficacy | Delta TC | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 3.25e-3 |
Statin Efficacy | Delta TG | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 1.32e-2 |
Statin Efficacy | Delta TG | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 4.43e-3 |
Statin Efficacy | Delta TG | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 2.77e-2 |
Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 1.00e-2 | 2.01e-2 |
Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 1.00e-3 | 9.47e-3 |
Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-3 | 4.27e-3 |
Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 5.00e-2 | 8.26e-3 |
Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-3 | 4.50e-2 |
Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-4 | 4.39e-2 |
Waist Format 1 | Hip Circumference European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 3.57e-2 |
Waist Format 1 | Hip Circumference European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 4.38e-2 |
Waist Format 1 | Hip Circumference Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 2.25e-2 |
Waist Format 1 | Waist Circumference European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 1.93e-2 |
Waist Format 1 | Waist Circumference Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 4.22e-2 |
Waist Format 1 | Waist Circumference Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 1.66e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 9.42e-4 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 8.06e-4 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 7.10e-3 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 1.07e-4 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 2.00e-3 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 1.15e-2 |
Waist Format 1 | Waist Hip Ratio Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 1.52e-2 |
Waist Format 2 | Hip Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 3.81e-2 |
Waist Format 2 | Hip Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 1.12e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 1.63e-8 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 2.89e-4 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-4 | 6.64e-4 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 8.70e-4 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 4.10e-7 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 9.67e-4 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 2.85e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-4 | 4.73e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-5 | 1.14e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 5.31e-4 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-2 | 2.78e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 7.71e-3 |
Waist Format 2 | Waist Hip Ratio European | MTC | Shungin | 2015 | NA | 143480 | 5.00e-2 | 2.36e-3 |
Waist Format 2 | Waist Hip Ratio European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 8.37e-3 |
Waist Format 2 | Waist Hip Ratio Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 1.87e-3 |
Waist Format 2 | Waist Hip Ratio Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 3.84e-4 |
Waist Format 2 | Waist Hip Ratio Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 1.23e-3 |
BIP | Bipolar disorder | ETC | Stahl | 2018 | 20352 | 31358 | 1.00e-4 | 4.51e-2 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-2 | 5.65e-4 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-3 | 1.09e-2 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-2 | 2.84e-9 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-3 | 2.70e-7 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-4 | 3.05e-4 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-5 | 9.45e-5 |
AUD | Alcohol Dependency | ETC | Walters | 2018 | 11569 | 34999 | 5.00e-2 | 1.90e-2 |
AUD | Alcohol Dependency | ETC | Walters | 2018 | 11569 | 34999 | 1.00e-3 | 3.58e-2 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-5 | 3.49e-2 |
CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 5.00e-2 | 4.37e-2 |
CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-2 | 1.29e-2 |
Glycine level | Glycine levels, both male and female | ETC | Jia | 2019 | NA | 30118 | 5.00e-2 | 3.49e-2 |
Ambidextrousness | Ambidextrousness | ETC | Kovel | 2019 | 5324 | 325713 | 5.00e-2 | 3.40e-3 |
Parkinsons | Parkinsons disease, age of onset | ETC | Blauwendraat | 2019 | NA | 17996 | 5.00e-2 | 4.99e-2 |
Active | Time to most active 10 hours | ETC | Jones | 2019 | NA | 85670 | 5.00e-2 | 2.39e-2 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 1.11e-3 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 6.03e-4 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 1.18e-3 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-5 | 4.78e-2 |
Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 6.84e-4 |
Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 1.37e-2 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 5.00e-2 | 9.24e-5 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 1.00e-2 | 4.35e-3 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 1.46e-2 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 4.84e-2 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 4.06e-2 |
Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 5.00e-2 | 1.99e-2 |
Neuroticism | Worry-vulnerability-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 5.00e-2 | 1.20e-2 |
Neuroticism | Worry-vulnerability-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-2 | 2.17e-2 |
Neuroticism | Anxiety-tension-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 5.00e-2 | 1.20e-2 |
Neuroticism | Anxiety-tension-special-factor-of-neuroticism | ETC | Hill | 2019 | NA | 270059 | 1.00e-2 | 2.17e-2 |
CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 5.00e-2 | 4.82e-3 |
CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-2 | 1.55e-2 |
CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-3 | 1.18e-4 |
Insomnia | Insomnia symptoms, never-rarely vs sometimes usually | ETC | Lane | 2019 | 345022 | 108357 | 1.00e-2 | 4.37e-2 |
BMI | Normal body mass index vs thin control, adult vs thin adult | ETC | McKay | 2019 | 6460 | 1471 | 1.00e-2 | 2.49e-2 |
Obesity | Obesity, extreme obese children vs control adult | ETC | McKay | 2019 | 1456 | 6460 | 5.00e-2 | 1.48e-2 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 4.25e-3 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-3 | 1.67e-2 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-4 | 2.57e-3 |
Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-5 | 3.23e-4 |
Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 1.76e-2 |
Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-3 | 9.88e-3 |
Body fat distribution | Body fat distribution-trunk-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-5 | 3.60e-2 |
Body fat distribution | Body fat distribution-arm-fat-ratio-female | ETC | Andersen | 2019 | NA | 116138 | 1.00e-3 | 2.14e-3 |
Body fat distribution | Body fat distribution-arm-fat-ratio-female | ETC | Andersen | 2019 | NA | 116138 | 1.00e-4 | 1.24e-2 |
Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-2 | 2.52e-5 |
Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-3 | 2.52e-2 |
Osteoarthritis | Osteoarthritis hip | ETC | Tachmazidou | 2019 | 15704 | 378169 | 5.00e-2 | 7.84e-4 |
Osteoarthritis | Osteoarthritis hip | ETC | Tachmazidou | 2019 | 15704 | 378169 | 1.00e-4 | 4.82e-2 |
Osteoarthritis | Knee osteoarthritis | ETC | Tachmazidou | 2019 | 24955 | 376169 | 5.00e-2 | 3.74e-2 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-2 | 4.50e-3 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-3 | 2.39e-4 |
Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-4 | 2.97e-3 |
Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 5.00e-2 | 4.08e-2 |
Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 1.00e-2 | 2.11e-3 |
Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 1.00e-3 | 4.31e-2 |
Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 1.00e-5 | 4.53e-2 |
Body fat | Body fat percentage | ETC | Hubel | 2018 | 70700 | 85261 | 1.00e-2 | 2.69e-2 |
Postburn scar pliability | Postburn scar pliability | ETC | Wallace | 2018 | NA | 665 | 5.00e-2 | 4.13e-2 |
Erectile dysfunction | Erectile dysfunction | ETC | Bovijn | 2018 | 6175 | 217630 | 5.00e-2 | 4.56e-3 |
Physical activity | Physical activity, overall physical activity time | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 8.00e-3 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 2.69e-3 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 1.06e-2 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-3 | 7.70e-3 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-4 | 1.13e-2 |
Sedentary behaviour duration | Sedentary behaviour duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-5 | 4.36e-2 |
Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 2.97e-2 |
Nonischemic cardiomyopathy | Nonischemic cardiomyopathy | ETC | Aragam | 2018 | 1816 | 388326 | 5.00e-2 | 6.38e-3 |
Heart failure | Heart failure | ETC | Aragam | 2018 | 6504 | 387652 | 1.00e-2 | 4.07e-2 |
Heart failure | Heart failure | ETC | Aragam | 2018 | 6504 | 387652 | 1.00e-3 | 1.30e-2 |
Heart failure | Heart failure | ETC | Aragam | 2018 | 6504 | 387652 | 1.00e-4 | 2.29e-2 |
Fimbria volume | Fimbria volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 4.89e-2 |
Brain volume | Dentate gyrus molecular layer volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.15e-2 |
Hippocampal volume | Total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.19e-3 |
Hippocampal volume | Total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 1.98e-2 |
Hippocampal volume | Hippocampal subfield CA1 volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.06e-3 |
Hippocampal volume | Hippocampal subfield CA1 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 3.82e-2 |
HATA volume | HATA volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 4.69e-2 |
Fimbria volume | Fimbria volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.93e-2 |
Hippocampal volume | Hippocampal tail volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 7.82e-4 |
Hippocampal volume | Hippocampal fissure volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 7.30e-3 |
Brain volume | Dentate gyrus molecular layer volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.05e-2 |
Brain volume | Dentate gyrus molecular layer volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 2.02e-4 |
Brain volume | Dentate gyrus granule cell layer volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.00e-3 |
Brain volume | Dentate gyrus granule cell layer volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 3.64e-2 |
Hippocampal volume | Hippocampal subfield CA4 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 7.58e-3 |
Hippocampal volume | Hippocampal subfield CA3 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.41e-2 |
Hippocampal volume | Hippocampal subfield CA1 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.98e-3 |
Hippocampal volume | Hippocampal subfield CA1 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 1.11e-2 |
Subiculum volume | Subiculum volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.65e-2 |
Parasubiculum volume | Presubiculum volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 1.91e-2 |
Parasubiculum volume | Presubiculum volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 1.95e-2 |
HATA volume | Hippocampal amygdala transition area volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.57e-2 |
Hippocampal volume | Hippocampal subfield CA3 volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.96e-2 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 5.00e-2 | 3.69e-6 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-2 | 3.17e-6 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-3 | 4.08e-6 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-4 | 2.74e-4 |
ACR | Urinary albumin to creatinine ratio | ETC | Zanetti | 2019 | NA | 218759 | 5.00e-2 | 2.84e-3 |
AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 5.00e-2 | 1.91e-2 |
AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 1.00e-2 | 1.92e-2 |
AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 1.00e-3 | 8.76e-3 |
AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 1.00e-4 | 1.13e-2 |
AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 1.00e-5 | 1.08e-2 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 5.00e-2 | 4.96e-2 |
Medication use | Medication use (vasodilators used in cardiac diseases) | ETC | Wu Y | 2019 | 5,546 | 237,113 | 5.00e-2 | 1.36e-2 |
Medication use | Medication use (vasodilators used in cardiac diseases) | ETC | Wu Y | 2019 | 5,546 | 237,113 | 1.00e-2 | 1.55e-2 |
Medication use | Medication use (beta blocking agents) | ETC | Wu Y | 2019 | 31,700 | 192,324 | 5.00e-2 | 7.21e-6 |
Medication use | Medication use (beta blocking agents) | ETC | Wu Y | 2019 | 31,700 | 192,324 | 1.00e-2 | 4.05e-5 |
Medication use | Medication use (beta blocking agents) | ETC | Wu Y | 2019 | 31,700 | 192,324 | 1.00e-3 | 2.24e-3 |
Medication use | Medication use (beta blocking agents) | ETC | Wu Y | 2019 | 31,700 | 192,324 | 1.00e-4 | 7.03e-4 |
Medication use | Medication use (beta blocking agents) | ETC | Wu Y | 2019 | 31,700 | 192,324 | 1.00e-5 | 9.20e-4 |
Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-2 | 5.37e-6 |
Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-3 | 2.53e-5 |
Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-4 | 8.15e-5 |
Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-5 | 1.23e-3 |
Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 1.00e-2 | 3.63e-6 |
Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 1.00e-3 | 1.14e-2 |
Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 1.00e-4 | 1.26e-2 |
Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 1.00e-5 | 1.20e-2 |
Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-3 | 2.07e-7 |
Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-4 | 3.76e-6 |
Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-5 | 5.60e-4 |
Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-2 | 3.06e-3 |
Medication use | Medication use (antimigraine preparations) | ETC | Wu Y | 2019 | 5,521 | 114,323 | 5.00e-2 | 9.36e-3 |
Medication use | Medication use (antimigraine preparations) | ETC | Wu Y | 2019 | 5,521 | 114,323 | 1.00e-2 | 1.14e-2 |
Medication use | Medication use (antimigraine preparations) | ETC | Wu Y | 2019 | 5,521 | 114,323 | 1.00e-4 | 7.91e-3 |
Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 5.00e-2 | 1.33e-2 |
Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 1.00e-2 | 1.73e-2 |
Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 5.00e-2 | 3.70e-3 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 5.00e-2 | 3.88e-5 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-2 | 1.45e-4 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-3 | 7.14e-6 |
Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 5.00e-2 | 1.73e-4 |
Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-2 | 6.00e-4 |
Blood urea nitrogen levels | Blood urea nitrogen levels | ETC | Wuttke M | 2019 | NA | 243,029 | 5.00e-2 | 2.42e-2 |
CKD | Chronic kidney disease | ETC | Wuttke M | 2019 | 64,164 | 561,055 | 1.00e-4 | 2.63e-2 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 5.00e-2 | 9.20e-8 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-2 | 3.26e-5 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-3 | 4.80e-5 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-4 | 3.80e-6 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-5 | 2.12e-3 |
Renal cell carcinoma | Renal cell carcinoma female | ETC | Laskar RS | 2019 | 1,992 | 3,095 | 1.00e-2 | 4.95e-2 |
Renal cell carcinoma | Renal cell carcinoma male | ETC | Laskar RS | 2019 | 3,227 | 4,916 | 1.00e-2 | 4.63e-3 |
Renal cell carcinoma | Renal cell carcinoma male | ETC | Laskar RS | 2019 | 3,227 | 4,916 | 1.00e-3 | 2.69e-3 |
Periodontal disease | Periodontal disease related phenotype (PCT2) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 3.37e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT2) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-3 | 2.97e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT3) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-3 | 1.56e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 1.29e-3 |
Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 3.19e-3 |
Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-3 | 1.56e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 1.30e-3 |
Autistic traits score | Autistic traits score (Social and Communication Disorders Checklist) | ETC | Massrali A | 2019 | NA | 5,628 | 5.00e-2 | 3.71e-2 |
Longevity | Longevity (age >90th survival percentile) | ETC | Deelen J | 2019 | 11,262 | 25,483 | 5.00e-2 | 1.98e-2 |
Longevity | Longevity (age >90th survival percentile) | ETC | Deelen J | 2019 | 11,262 | 25,483 | 1.00e-2 | 1.65e-2 |
Longevity | Longevity (age >99th survival percentile) | ETC | Deelen J | 2019 | 3,484 | 25,483 | 5.00e-2 | 4.37e-2 |
Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-2 | 1.04e-2 |
same-sex sexual behaviour | same-sex sexual behaviour Female | ETC | Ganna A | 2019 | NA | 220,170 | 5.00e-2 | 1.26e-2 |
Knee pain | Knee pain | ETC | Meng W | 2019 | 22,204 | 149,312 | 5.00e-2 | 2.35e-2 |
Knee pain | Knee pain | ETC | Meng W | 2019 | 22,204 | 149,312 | 1.00e-2 | 5.94e-3 |
Occipital lobe volume | Occipital lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 4.18e-2 |
Parietal lobe volume | Parietal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 1.12e-2 |
Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 6.06e-5 |
Frontal lobe volume | Frontal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 6.31e-3 |
Frontal lobe volume | Frontal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-2 | 2.88e-3 |
Birth | Gestational age at birth (child effect) | ETC | Liu X | 2019 | NA | 84,689 | 5.00e-2 | 8.05e-4 |
Birth | Gestational age at birth (child effect) | ETC | Liu X | 2019 | NA | 84,689 | 1.00e-2 | 7.06e-3 |
Birth | Post-term birth | ETC | Liu X | 2019 | 7,888 | 60,148 | 5.00e-2 | 4.44e-2 |
Birth | Early spontaneous preterm birth | ETC | Liu X | 2019 | 1,139 | 60,148 | 5.00e-2 | 1.35e-2 |
Birth | Early spontaneous preterm birth | ETC | Liu X | 2019 | 1,139 | 60,148 | 1.00e-2 | 7.06e-3 |
Birth | Early spontaneous preterm birth | ETC | Liu X | 2019 | 1,139 | 60,148 | 1.00e-3 | 2.29e-2 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-2 | 2.13e-2 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-3 | 2.11e-2 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-4 | 1.16e-2 |
Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 5.00e-2 | 8.25e-3 |
Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 5.00e-2 | 1.54e-2 |
Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-2 | 3.02e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-3 | 9.81e-7 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-4 | 1.80e-7 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-5 | 1.65e-4 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-2 | 2.87e-5 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-3 | 1.26e-2 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-4 | 2.51e-3 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-5 | 3.52e-3 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-4 | 1.96e-7 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 697,734 | 1.00e-5 | 1.03e-5 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-3 | 4.76e-7 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-4 | 2.98e-6 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 381,152 | 1.00e-5 | 3.05e-3 |
Waist to hip ratio | Waist-hip ratio | ETC | Pulit SL | 2019 | NA | 316,772 | 1.00e-2 | 9.57e-3 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-4 | 3.29e-10 |
Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-5 | 3.54e-6 |
Joint damage | Joint damage in rheumatoid arthritis | ETC | Traylor M | 2019 | NA | 2,527 | 5.00e-2 | 3.38e-2 |
AD | Alzheimer's disease | ETC | Moreno-Grau S | 2019 | 4,120 | 3,289 | 5.00e-2 | 2.83e-2 |
BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 5.00e-2 | 2.66e-3 |
Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 5.00e-2 | 2.80e-2 |
Lung function | Lung function (forced vital capacity) variance | ETC | Wang H | 2019 | NA | 317,222 | 5.00e-2 | 2.06e-2 |
Lung function | Lung function (FEV1) variance | ETC | Wang H | 2019 | NA | 317,285 | 5.00e-2 | 3.33e-3 |
Birth weight | Birth weight variance | ETC | Wang H | 2019 | NA | 197,758 | 5.00e-2 | 1.18e-2 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 5.00e-2 | 4.60e-4 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-2 | 3.85e-3 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-3 | 4.08e-2 |
Heavy menstrual bleeding | Heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 9,813 | 210,946 | 1.00e-2 | 1.25e-2 |
Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 5.00e-2 | 1.25e-2 |
Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-2 | 1.16e-2 |
Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-3 | 8.76e-3 |
Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-4 | 3.40e-2 |
BMI at birth | BMI at birth | ETC | Helgeland O | 2019 | NA | 9,286 | 5.00e-2 | 5.48e-3 |
BMI at birth | BMI at birth | ETC | Helgeland O | 2019 | NA | 9,286 | 1.00e-2 | 2.45e-2 |
BMI by age | BMI at 3 months old | ETC | Helgeland O | 2019 | NA | 7,970 | 5.00e-2 | 3.34e-2 |
BMI by age | BMI at 6 months old | ETC | Helgeland O | 2019 | NA | 8,017 | 5.00e-2 | 1.31e-3 |
BMI by age | BMI at 8 months old | ETC | Helgeland O | 2019 | NA | 7,197 | 5.00e-2 | 3.08e-2 |
BMI by age | BMI at 2 years old | ETC | Helgeland O | 2019 | NA | 4,631 | 5.00e-2 | 1.99e-2 |
BMI by age | BMI at 3 years old | ETC | Helgeland O | 2019 | NA | 5,069 | 5.00e-2 | 1.94e-2 |
BMI by age | BMI at 3 years old | ETC | Helgeland O | 2019 | NA | 5,069 | 1.00e-2 | 1.42e-2 |
BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 5.00e-2 | 4.54e-4 |
BMI by age | BMI at 8 years old | ETC | Helgeland O | 2019 | NA | 3,862 | 5.00e-2 | 3.10e-3 |
Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 5.00e-2 | 4.25e-2 |
Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 1.00e-2 | 4.47e-2 |
Left ventricular | Left ventricular end-systolic volume | ETC | Aung N | 2019 | NA | 16,920 | 5.00e-2 | 1.39e-5 |
Left ventricular | Left ventricular end-systolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-2 | 1.15e-4 |
Left ventricular | Left ventricular ejection fraction | ETC | Aung N | 2019 | NA | 16,923 | 5.00e-2 | 2.07e-2 |
Left ventricular | Left ventricular mass | ETC | Aung N | 2019 | NA | 16,920 | 5.00e-2 | 1.14e-2 |
Left ventricular | Left ventricular mass | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-2 | 1.32e-3 |
Left ventricular | Left ventricular end-diastolic volume | ETC | Aung N | 2019 | NA | 16,920 | 5.00e-2 | 1.86e-2 |
Left ventricular | Left ventricular end-diastolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-2 | 2.91e-2 |
Left ventricular | Left ventricular end-diastolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-4 | 3.19e-2 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 5.00e-2 | 1.37e-7 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-2 | 1.07e-3 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-3 | 3.04e-4 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-5 | 1.56e-2 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 5.00e-2 | 1.97e-5 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-2 | 2.76e-3 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-3 | 6.17e-3 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-4 | 9.41e-4 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 5.00e-2 | 7.72e-4 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-2 | 1.42e-4 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-3 | 1.49e-3 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-4 | 9.72e-4 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-5 | 1.95e-3 |
Temporale asymmetry | Planum temporale asymmetry index | ETC | Carrion-Castillo A | 2020 | NA | 18,049 | 5.00e-2 | 4.95e-2 |
Temporale grey matter volume | Left planum temporale grey matter volume | ETC | Carrion-Castillo A | 2020 | NA | 18,037 | 5.00e-2 | 8.70e-5 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-2 | 1.68e-3 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-3 | 1.23e-4 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-4 | 3.01e-3 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-5 | 4.09e-3 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-2 | 8.20e-4 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-3 | 1.68e-2 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-4 | 3.17e-2 |
Household income | Household income | ETC | Hill WD | 2019 | NA | 286,301 | 5.00e-2 | 3.19e-2 |
CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.83e-2 |
IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 7.24e-3 |
IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 1.20e-2 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.02e-3 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 1.36e-2 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 1.06e-2 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.83e-2 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 2.97e-2 |
MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 8.32e-3 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.23e-3 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 6.23e-4 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 1.98e-4 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 3.88e-4 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 7.76e-3 |
Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 4.48e-2 |
Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 4.35e-2 |
IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.23e-2 |
Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 4.02e-5 |
Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 5.98e-3 |
E-selectin | E-selectin levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.43e-3 |
E-selectin | E-selectin levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 4.00e-4 |
E-selectin | E-selectin levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 2.79e-2 |
E-selectin | E-selectin levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.72e-2 |
Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.65e-2 |
Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 4.15e-2 |
Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 3.91e-2 |
Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 1.00e-2 | 2.14e-2 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 1.00e-2 | 2.88e-2 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 1.00e-3 | 4.47e-2 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 1.00e-4 | 2.86e-2 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 1.95e-13 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 4.03e-11 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-3 | 7.43e-8 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-4 | 2.17e-7 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-5 | 3.64e-8 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-2 | 1.46e-2 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-3 | 3.72e-2 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-2 | 7.80e-3 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-3 | 1.49e-2 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-5 | 2.10e-2 |
Snoring | Snoring male | ETC | Campos AI | 2020 | 90,806 | 99,165 | 5.00e-2 | 1.39e-4 |
Snoring | Snoring male | ETC | Campos AI | 2020 | 90,806 | 99,165 | 1.00e-2 | 1.24e-3 |
Snoring | Snoring male | ETC | Campos AI | 2020 | 90,806 | 99,165 | 1.00e-3 | 3.27e-3 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 5.00e-2 | 9.91e-4 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 1.00e-2 | 3.31e-3 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 1.00e-3 | 4.15e-2 |
Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 1.00e-4 | 2.73e-2 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 5.00e-2 | 3.63e-2 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-2 | 4.48e-3 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-3 | 4.19e-2 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-4 | 1.54e-2 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-5 | 4.36e-2 |
COVID-19 Host Genetics | hospitalized covid vs. not hospitalized covid (EA) | ETC | covid19hg | 2020 | 928 | 2028 | 5.00e-2 | 2.51e-2 |
COVID-19 Host Genetics | hospitalized covid vs. not hospitalized covid (EA) | ETC | covid19hg | 2020 | 928 | 2028 | 1.00e-2 | 4.74e-3 |
COVID-19 Host Genetics | predicted covid from self-reported symptoms vs. predicted or self-reported non-covid (EA) | ETC | covid19hg | 2020 | 1865 | 29174 | 5.00e-2 | 8.50e-5 |
COVID-19 Host Genetics | predicted covid from self-reported symptoms vs. predicted or self-reported non-covid (EA) | ETC | covid19hg | 2020 | 1865 | 29174 | 1.00e-2 | 2.91e-2 |
COVID-19 | Severe COVID-19 infection with respiratory failure (analysis II) | ETC | Ellinghaus D | 2020 | 1610 | 2180 | 5.00e-2 | 5.84e-3 |
Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 5.00e-2 | 2.15e-3 |
Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-5 | 4.92e-2 |
COVID-19 | COVID-19 UKBB EUR tested (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 5,455 | 1.00e-2 | 2.55e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.